ArticleCureus2026
Persistent Epithelial Defect After Bullae Rupture With Netarsudil.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 61-year-old male patient presented with reticular epithelial edema (REE) and bullae in the inferonasal quadrant of the right eye (RE) one month after initiation of topical netarsudil 0.02%. The findings were confirmed on anterior segment optical coherence tomography (AS-OCT). Following discontinuation of the medication, the epithelial edema resolved over a period of six weeks. Nine months later, the patient re-presented with redness, increased lacrimation, and blurred vision in the RE, occurring two weeks after re-initiation of topical netarsudil 0.02%. Slit-lamp examination revealed REE with a few bullae and an epithelial defect in the inferonasal paracentral cornea, corresponding to the location of the previous lesion. Corneal sensations were absent over and in the surrounding area of the lesion. AS-OCT confirmed the presence of epithelial edema and bullae. Netarsudil was promptly discontinued. The patient was managed with topical lubricants, and a bandage contact lens was applied. Due to a persistent epithelial defect, he subsequently underwent amniotic membrane transplantation combined with lateral tarsorrhaphy. Four weeks later, the epithelial defect had healed, leaving a residual nebular corneal opacity. He later underwent implantation of an Ahmed glaucoma valve (AGV) for intraocular pressure (IOP) control. Ophthalmologists should be cognizant of the potential corneal adverse effects associated with netarsudil, including REE and bullae formation. In cases of persistent epithelial defects, underlying predisposing factors should be carefully evaluated and managed appropriately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.